Scandion Oncology

Overcoming cancer drug resistance

Navbar
  • About us
    • Executive Management
    • Board of Directors
    • Clinical Advisory Board
  • Research & Development
    • Pipeline
    • Clinical Development
    • Science
      • Cancer drug resistance
      • Technology Platform
      • SCO-101
  • Press releases
  • Investors & Media
    • Share information
    • Financial Reports
      • Annual reports
      • Interim reports
      • Year-end reports
    • Presentations
    • Media
      • Image library
      • Video library
    • Analyst Coverage
    • Prospectuses
      • Rights Issue 2022
      • Rights Issue 2020
      • Rights Issue 2019
      • Subscription Warrant (SCOL TO 1)
      • IPO 2018
    • Corporate governance
    • Events
      • Financial calendar
      • General meetings
  • Contact
    • Career
    • Business development
Skip to content

Press releases

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
AllRegulatory posts
18 December 2020 Letter from the CEO: Great progress in 2020 – we are ready for 2021! Download Presentation Webcast Workbook
24 April 2020 Presentation of the ongoing Clinical Phase II trial at the AACR Virtual Annual Meeting Download Presentation Webcast Workbook
26 March 2020 Scandion Oncology CEO Newsletter (March 2020) Download Presentation Webcast Workbook
27 January 2020 Scandion Oncology Newsletter 27 January, 2020 Download Presentation Webcast Workbook
21 January 2020 Scandion Oncology Newsletter 21st January, 2020 Download Presentation Webcast Workbook
14 January 2020 Scandion Oncology News, January 2020 Download Presentation Webcast Workbook
21 November 2019Regulatory Scandion Oncology CEO Newsletter November 2019 Download Presentation Webcast Workbook
24 September 2019 Scandion Oncology CEO Newsletter autumn 2019 Download Presentation Webcast Workbook
21 August 2019 Update on Q & A Download Presentation Webcast Workbook

Information types

Choose your information types.

Stay updated with news from Scandion Oncology

Subscribe below

Subscription successful. To activate the subscription, we request that you confirm your e-mail address. Do this by clicking on this link in the email we just sent you.
Subscription failed. Error:
  1. Frontpage
  2. Press releases
  3. Newsletter

About us

  • About us
  • Executive Management
  • Board of Directors
  • Clinical Advisory Board

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Development
  • Science
  • Patents

Investors & Media

  • Investors & Media
  • Share information
  • Financial Reports
  • Presentations
  • Media
  • Analyst Coverage
  • Prospectuses
  • Corporate governance
  • Events

Contact us

Scandion Oncology A/S
Symbion
Fruebjergvej 3
2100 Copenhagen
Denmark

Phone: +45 38 10 20 17
info@scandiononcology.com

Media and Investor relations:
Email: ir@scandiononcology.com
Phone: +45 29 60 35 32

Follow us

Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Cookie settings | Disclaimer: Market data could be delayed. Delivered by Cision.

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all